Abstract:Pancreatic cancer is a significant challenge in oncology due to its aggressive nature and complex management, leading to high mortality rates and a dismally low 5-year survival rate. Approximately 85% of cases manifest as adenocarcinoma, while endocrine tumors constitute less than 5%. Borderline resectable and locally advanced pancreatic cancers are particularly difficult to treat due to vascular involvement, which complicates complete resections and increases morbidity. Various therapeutic modalities aim to overcome these challenges and improve patient outcomes. Traditionally, upfront surgery was the standard for resectable tumors, with multimodal chemotherapy being central to treatment. Understanding surgical anatomy is pivotal in enhancing surgical outcomes and patient survival. Resectability challenges are several when seeking to achieve R0 resections, particularly for borderline resectable tumors. Various classification systems—the MD Anderson criteria, the NCCN criteria, the AHPA/SSAT/SSO consensus statement, and the Alliance definition—assess tumor involvement with major blood vessels, with the first of these systems being broadly accepted. Vascular staging integration is also important, with the Ishikawa staging system using preoperative imaging to assess venous involvement. Furthermore, neoadjuvant therapy enhances treatment effectiveness by addressing micro-metastatic disease early, increasing R0 resection chances, and downstaging tumors for optimal surgery. Insights from the Fox Chase Cancer Center's neoadjuvant treatment approach highlight the importance of a multidisciplinary strategy when advancing therapy and improving patient prognosis. This commentary, inspired by Dr. Sanjay S. Reddy's Keynote Conference during MedNews week, highlights current advancements and ongoing challenges in the treatment of pancreatic cancer, emphasizing the need for a comprehensive, multidisciplinary approach to improve outcomes.

Novel Considerations in Surgical Management of Individuals with Pancreatic Adenocarcinoma

Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoma

Adjuvant Chemotherapy, with or Without Postoperative Radiotherapy, for Resectable Advanced Pancreatic Adenocarcinoma: Continue or Stop?

Neoadjuvant and Adjuvant Therapy in Resectable Pancreatic Adenocarcinoma

Advancing Pancreatic Cancer Surgical Treatments and Proposal of New Approaches

Preoperative therapy for pancreatic adenocarcinoma—precision beyond anatomy

Neoadjuvant treatment for pancreatic cancer: Controversies and advances

Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer

Current Status and Perspectives of Neoadjuvant Therapy for Pancreatic Cancer

Contemporary Approaches to the Surgical Management of Pancreatic Neuroendocrine Tumors

Advances Of Stereotactic Body Radiotherapy In Pancreatic Cancer

Surgical management of pancreatic ductal adenocarcinoma: a narrative review

[Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer]

Current surgical concepts and future perspectives in the treatment of pancreatic cancer

When, What, and Why of Perioperative Treatment of Potentially Curable Pancreatic Adenocarcinoma

Surgery for Pancreatic Cancer: Recent Controversies and Current Practice

Developments in pancreatic cancer surgery

Neoadjuvant treatment of pancreatic ductal adenocarcinoma: Whom, when and how

The Evolving Role of Neoadjuvant Radiation Therapy in Pancreatic Adenocarcinoma

Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer

Anatomical and Biological Considerations to Determine Resectability in Pancreatic Cancer